Recipharm

Recipharm AB operates as a pharmaceutical contract development and manufacturing company. Its dosage forms include solid dose, steriles, semi solids, beta-lactams, hormones, dry powder inhalers, granulates, and powders. The company provides pharmaceutical development services, such as formulation development, clinical supplies, analytical development, stability studies, packaging development and selection, and raw material selection; and manufacturing services. It also offers EU gateway release and testing, regulatory, stability studies, and customized services. Recipharm AB was founded in 1995 and is based in Haninge, Sweden. It has manufacturing facilities in Sweden, France, and the United Kingdom.

Company Growth (employees)
Type
Public
HQ
Stockholm, SE
Size (employees)
2,838 (est)+8%
Recipharm is headquartered in Stockholm, SE

Key People at Recipharm

Thomas Eldered

Thomas Eldered

CEO
Sture Nordberg

Sture Nordberg

Vice President of Science & Technology

Recipharm Office Locations

Recipharm has an office in Stockholm
Stockholm, SE (HQ)
Lagervagen 7

Recipharm Data and Metrics

Recipharm Financial Metrics

Recipharm's revenue was reported to be kr3.5 b in FY, 2015 which is a 32% increase from the previous period.
SEK

Revenue (FY, 2015)

3.5 b

Revenue growth (FY, 2014 - FY, 2015), %

32%

Gross profit (FY, 2015)

2.6 b

Gross profit margin (FY, 2015), %

73%

Net income (FY, 2015)

215.1 m

EBITDA (FY, 2015)

509.8 m

EBIT (FY, 2015)

274.2 m

Market capitalization (24-Jul-2017)

7.6 b

Closing share price (24-Jul-2017)

120.3

Cash (31-Dec-2015)

534.2 m

EV

8.8 b
Recipharm's current market capitalization is kr7.6 b.
SEKFY, 2014FY, 2015

Revenue

2.7 b3.5 b

Revenue growth, %

32%

Cost of goods sold

703.9 m958.8 m

Gross profit

2 b2.6 b

Gross profit Margin, %

74%73%

Sales and marketing expense

588.7 m799.7 m

General and administrative expense

888.6 m1.2 b

Operating expense total

1.5 b2 b

Depreciation and amortization

127.2 m235.6 m

EBITDA

399.3 m509.8 m

EBITDA margin, %

15%14%

EBIT

272.1 m274.2 m

EBIT margin, %

10%8%

Interest expense

65.4 m29 m

Interest income

9.3 m64.4 m

Pre tax profit

216.1 m309.6 m

Income tax expense

55.9 m94.6 m

Net Income

160.2 m215.1 m
SEKY, 2014Y, 2015

Cash

404.5 m534.2 m

Total Assets

5.4 b5.7 b

Total Debt

1.6 b1.7 b

Total Liabilities

5.4 b3 b
SEKFY, 2014FY, 2015

Cash From Operating Activities

254.2 m428.8 m
SEKY, 2015

EV/EBITDA

17.3 x

EV/EBIT

32.1 x

EV/CFO

20.6 x

Revenue/Employee

7.2 m

Recipharm Market Value History

Recipharm Revenue Breakdown

Traffic Overview of Recipharm

Recipharm Company Life and Culture

You may also be interested in